Proteomics, the large-scale study of proteins, is revolutionizing biotechnology by providing unprecedented insights into disease mechanisms, diagnostics, and drug development. The global proteomics market was valued at $30.61 billion in 2023 and is projected to reach $96.35 billion by 2032, growing at a CAGR of 13.61%. Advances in AI-driven data analysis, high-throughput screening, and single-molecule proteomics are fueling this rapid expansion.
This article highlights 10 pioneering biotech companies that are leading breakthroughs in proteomics, reshaping healthcare, and advancing life sciences.
What is Proteomics?
Proteomics is the large-scale study of proteins—their structures, modifications, interactions, and functions. Unlike genomics, which provides a static genetic blueprint, proteomics reveals the dynamic behavior of proteins in response to biological changes. This deeper understanding allows researchers to decode complex biological systems and identify critical biomarkers for diseases.
Why is proteomics important?
- Biomarker Discovery: Identifies proteins linked to diseases for early detection and precision diagnostics.
- Drug Development: Helps validate drug targets and optimize therapeutic strategies.
- Personalized Medicine: Enables customized treatments based on a patient’s proteomic profile.
- Systems Biology: Integrates proteomics with genomics and metabolomics for a comprehensive view of biological networks.
Top 10 Proteomics Companies to Watch in 2025
Alamar Biosciences has developed the NULISA™ platform, which offers attomolar sensitivity for protein detection. This technology uses a sequential immunocomplex capture and release mechanism combined with next-generation sequencing, allowing for the detection of low-abundance biomarkers. The platform supports both single-plex and multiplex assays, enabling researchers to analyze a wide range of proteins from a single sample. Alamar's ARGO™ HT System automates this process, providing results in under 16 hours with minimal hands-on time.
Acrivon Therapeutics utilizes its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop patient selection tests called OncoSignature®. These tests identify patients most likely to benefit from specific drugs by measuring disease-driving protein mechanisms directly from tumor biopsies. The AP3 platform integrates high-resolution mass spectrometry for biomarker identification with automated tumor biopsy imaging for validation. This approach aims to match therapies to patients based on the active biology of their tumors, independent of genetic mutations.
Interline Therapeutics focuses on understanding and targeting protein communities within cells to discover new treatments. By studying how proteins interact and form networks, Interline aims to identify key points where interventions can be most effective. Their approach combines structural biology, computational modeling, and chemical biology to develop therapies for diseases such as cancer and autoimmune disorders.
ProFound Therapeutics has expanded the known human proteome by discovering thousands of previously unidentified proteins. Their ProFoundry™ platform uses advanced proteomic techniques to map these novel proteins and understand their functions. This expanded view of the proteome opens up new possibilities for developing biologics, RNA-based therapies, and gene editing strategies to treat various diseases.
Sengenics specializes in functional proteomics and autoantibody profiling using their KREX™ technology. This platform ensures that proteins are correctly folded and functional, allowing for accurate detection of autoantibodies. Sengenics applies this technology to identify biomarkers for early cancer detection, autoimmune diseases, and to support vaccine development. Their research includes developing immune monitoring panels to personalize immunotherapy treatments.
PrognomiQ is at the forefront of integrating proteomics with other omics data to transform disease detection and treatment. By generating extensive proteomic data and complementing it with genomic and metabolomic information, PrognomiQ aims to develop transformative test products for early disease detection. Their proprietary multi-omics platform is designed to provide deep insights into the biological state of individuals, facilitating the early identification and treatment of complex diseases such as cancer.
Adeptrix Corporation has developed the Bead-Assisted Mass Spectrometry (BAMS) platform, which combines the specificity of immunoassays with the sensitivity of mass spectrometry. This hybrid approach allows for the simultaneous detection of multiple protein biomarkers with high sensitivity. BAMS is applied in various fields, including infectious disease research, pharmacokinetics, and clinical proteomics. The company is also advancing customized mass spectrometry panels tailored for personalized medicine applications, enhancing the precision of diagnostics and treatments.
Sirona Dx is a specialized contract research organization (CRO) offering highly multiplexed single-cell proteomics solutions. They provide comprehensive assay development, validation, and regulatory support services to biotech and pharmaceutical companies. Their high-resolution tissue imaging and spatial proteomics capabilities are instrumental in accelerating biomarker-driven drug discovery and advancing precision oncology research. By enabling detailed analysis of protein expression at the single-cell level, Sirona Dx supports the development of targeted therapies and personalized treatment strategies.
NanoMosaic is pioneering the use of nanoneedle-based technology for protein interrogation. Their Tessie™ platform enables real-time, label-free protein analysis with femtomolar sensitivity, allowing for the detection of extremely low-abundance proteins. This ultra-sensitive, chip-based platform is designed for applications in early disease detection, biomarker validation, and high-throughput proteomics. By providing rapid and accurate protein measurements, NanoMosaic's technology has the potential to significantly impact clinical diagnostics and biomedical research.
Nautilus Biotechnology is developing a single-molecule proteomics platform capable of comprehensively analyzing and quantifying the entire proteome. Their system integrates machine learning, nanoscale sensors, and massively parallel protein sequencing to accelerate drug target identification and biomarker discovery. This approach aims to provide a comprehensive view of protein dynamics in health and disease. As of late 2024, Nautilus has faced challenges in developing reagents for its platform, leading to adjustments in its projected launch timeline to late 2025 or possibly 2026
Conclusion
Proteomics is reshaping life sciences, fueling breakthroughs in biomarker discovery, drug development, and personalized medicine. The 10 biotech companies featured in this blog are leading the way, harnessing proteomics to transform patient care and solve complex biological challenges.
